Recurrence, Progression, and Follow-Up in Non-Muscle-Invasive Bladder Cancer

European Urology, Supplements

Volumn 8, Issue 7, 2009, Pages 556-562

  van der Heijden, Antoine G ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EORTC risk tables; Fluorescence cystoscopy; Follow up; Non muscle invasive bladder cancer; Progression; Recurrence; Urine markers

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; MITOMYCIN C; PROTEIN P53;

ANAMNESIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTOSCOPY; DRUG WITHDRAWAL; FLUORESCENCE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIFESTYLE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSURETHRAL RESECTION; URINALYSIS;

EID: 67651054951     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.06.010     Document Type: Review

References (67)

1. Parkin D.M. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 218 (2008) 12-20
2. Ferlay J., Randi G., Bosetti C., et al. Declining mortality from bladder cancer in Europe. BJU Int 101 (2008) 11-19
3. Oosterlinck W., Lobel B., Jakse G., Malmström P.U., Stöckle M., Sternberg C., and The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
4. Botteman M.F., Pashos C.L., Redaelli A., Laskin B., and Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21 (2003) 1315-1330
5. Castelao J.E., Yuan J.M., Skipper P.L., et al. Gender- and smoking-related bladder cancer risk. J Natl Cancer Inst 93 (2001) 538-545
6. Murta-Nascimento C., Schmitz-Dräger B.J., Zeegers M.P., et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 25 (2007) 285-295
7. Colombel M., Soloway M., Akaza H., et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl 7 (2008) 618-626
8. Narayana A.S., Loening S.A., Slymen D.J., and Culp D.A. Bladder cancer: factors affecting survival. J Urol 130 (1983) 56-60
9. Parmar M.K., Freedman L.S., Hargreave T.B., and Tolley D.A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 142 (1989) 284-288
10. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., Palou J., and Vicente-Rodríguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 163 (2000) 73-78
11. Shinka T., Hirano A., Uekado Y., and Ohkawa T. Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin. Br J Urol 66 (1990) 35-39
12. Kiemeney L.A., Witjes J.A., Heijbroek R.P., Debruyne F.M., and Verbeek A.L. Dysplasia in normal-looking urothelium increases the risk of tumor progression in primary superficial bladder cancer. Eur J Cancer 30A (1994) 1621-1625
13. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer 31A (1995) 1840-1846
14. Heney N.M., Ahmed S., Flanagan M.J., Frable W., Corder M.P., Hafermann M.D., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083-1086
15. Kondo T., Onitsuka S., Ryoji O., et al. Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy. Int J Urol 6 (1999) 178-183
16. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
17. Oosterlinck W., Kurth K.H., Schröder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
18. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin-C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
19. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163 (2000) 1124-1129
20. Van der Meijden A.P.M., Sylvester R.J., Oosterlinck W., Hoeltl W., Bono A.V., and for the EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44 (2003) 429-434
21. van Rhijn B.W.G. Considerations on the use of urine markers for bladder cancer. Eur Urol 53 (2008) 880-881
22. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on Bladder Tumor Markers. Urology 66 Suppl 1 (2005) 35-63
23. Vrooman O.P.J., and Witjes J.A. Urinary markers in bladder cancer. Eur Urol 53 (2008) 909-916
24. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
25. ® test in the diagnosis of superficial bladder cancer. Eur Urol 48 (2005) 951-956
26. Van Rhijn B.W.G., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 47 (2005) 736-748
27. van der Aa M.N.M., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite analysis of voided-urine samples for surveillence of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 55 (2009) 659-668
28. Brausi M., Collette L., Kurth K., et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
29. Zaak D., Hungerhuber E., Schneede P., et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 95 (2002) 1234-1238
30. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., and Marberger M. Hexvix PCB301/01 Study Group. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
31. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174 (2005) 862-866
32. Grossman H.B., Gomella L., Fradet Y., et al. PC B302/01 Study Group. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
33. Fradet Y., Grossman H.B., Gomella L., et al. PC B302/01 Study Group. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73
34. Hungerhuber E., Stepp H., Kriegmair M., et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 69 (2007) 260-264
35. Karl A., Tritschler S., Stanislaus P., et al. Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?. BJU Int 103 (2009) 484-487
36. Denziger S., Burger M., Walter B., et al. Clinically relevant risk of reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid induced fluorescence diagnosis: 8-year results of a prospective randomized study. Urology 69 (2007) 675-679
37. Daniltschenko D.I., Riedl C.R., Sachs M.D., et al. Longterm benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
38. Sylvester R.J. Natural history, recurrence and progression in superficial bladder cancer. TSW Urology 1 (2006) 15-23
39. Fernandez-Gomez J., Solsona E., Unda M., et al. Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
40. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
41. Skinner E.C. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 25 (2007) 523-525
42. Chang S.S., and Cookson M.S. Radical cystectomy for bladder cancer: the case for early intervention. Urol Clin North Am 32 (2005) 147-155
43. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
44. Hurle R., Losa A., Manzetti A., and Lembo A. Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54 (1999) 258-263
45. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51 (2007) 152-160
46. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
47. van Oers J.M.M., Zwarthoff E.C., Rehman I., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumors. Eur Urol 55 (2009) 650-658
48. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., and Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
49. Hernández S., López-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
50. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
51. Tsuji M., Kojima K., Murakami Y., Kanayama H., and Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 79 (1997) 367-372
52. Asakura T., Takano Y., Iki M., et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 158 (1997) 385-388
53. Holmäng S., Andius P., Hedelin H., Wester K., Busch C., and Johansson S.L. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 165 (2001) 1124-1128
54. Christoph F., Weikert S., Wolff I., et al. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder. Cancer Lett 8 (2007) 121-126 245
55. Harnden P., Mahmood N., and Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 353 (1999) 974-977
56. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumors and implications for therapy. Eur Urol 45 (2004) 292-296
57. van Oers J.M.M., Wild P.J., Burger M., et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 52 (2007) 760-768
58. Burger M., van der Aa M.N.M., van Oers J.M.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54 (2008) 835-844
59. van Rhijn B.W.G., Smit M., van Geenen D., et al. Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy. Eur Urol 43 (2003) 369-373
60. Gofrit O.N., Pode D., Lazar A., Katz R., and Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol 49 (2006) 303-306
61. Soloway M.S., Bruck D.S., and Kim S.S. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170 (2003) 438-441
62. Zieger K., Wolf H., Olsen P.R., and Hojgaard K. Long-term follow-up of noninvasive bladder tumors (stage Ta): recurrence and progression. BJU Int 85 (2000) 824-828
63. Sylvester R.J., Oosterlinck W., and van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
64. Mariappan P., and Smith G. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol 173 (2005) 1108-1111
65. Mariappan P., Smith G., Lamb A.D., Grigor K.M., and Tolley D.A. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol 177 (2007) 867-875
66. Dalesio O., Schulman C.C., Sylvester R., et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 129 (1983) 730-733
67. Mulders P.F., Meyden A.P., Doesburg W.H., Oosterhof G.O., and Debruyne F.M. Prognostic factors in pTa-pT1 superficial bladder tumors treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 73 (1994) 403-408